We’re honored to be named to the 2026 #Endpoints11. This recognition reflects the support of our investors and Board and we look forward to the work ahead as we advance STP-100 toward the clinic in early 2027. Read more: bit.ly/3TLPq4F
0:17
Stipple Bio
Verified account This account is verified. Learn more@stipplebio
Stipple Bio is a biotechnology company harnessing epitope-level precision to create targeted cancer therapies through our proprietary Pointillist Platform.
8 Following 69 Followers 10 Posts
Latest posts 5
We’ve appointed seasoned biopharma exec, Roland Gendron, as Chief Business Officer to lead corporate and business development, strategic partnerships, alliance management and corporate strategy initiatives at Stipple Bio. Welcome to the team, Roland! bit.ly/3RiUCvA
0:24
We’ve entered into a multi-target licensing agreement with @LonzaGroup to support the development of #precisiononcology #ADC therapies, including STP-100, combining our Pointillist Platform, with Lonza’s clinically validated GlycoConnect® ADC platform. Learn more: bit.ly/4dXV4qs
0:24
Excited to be featured in @BioCentury, highlighting our epitope-level approach to identifying tumor-specific targets and enabling more selective #cancer therapies. Read more: bit.ly/4sBEiTp
www.biocentury.com Stipple: Epitope-level precision for safer cancer therapies Stipple emerged from stealth this week with an oversubscribed $100 million series A financing, joining a growing group of biotechs with platforms to s... Following our recent Series A news, we’re excited to be featured on the Nasdaq Tower in Times Square. Thank you to @Nasdaq for the spotlight. #PrecisionOncology
